Blogs
Welcome to Unibest's Blogs section! Here, you will find valuable insights and in-depth reports covering various topics related to drugs and diseases. Our blogs aim to provide an enhanced understanding of the clinical significance and breakthroughs your clients can make. Stay updated with the latest trends, technological advancements, and industry analyses as we dive deep into the world of pharmaceuticals, giving you the knowledge and resources you need to stay ahead of the competition.

Binimetinib

These are related to the Binimetinib news, in which you can learn about the latest trends in Binimetinib and related information industry, to help you better understand and expand Binimetinib market.
  • Drug Patent & Exclusivity Expiration Report - Week of March 10 2025

    Drug Patent & Exclusivity Expiration Report - Week of March 10 2025

    2025-03-10

    This week, there are 16 drugs in the patent and exclusivity list. They are: - Yupelri by Mylan Ireland Ltd, containing active ingredient Revefenacin - Xiidra by Bausch and Lomb Inc, containing active ingredient Lifitegrast - Ogsiveo by Springworks Therapeutics Inc, containing active ingredient Nirogacestat Hydrobromide - Koselugo by AstraZeneca Pharmaceuticals LP, containing active ingredient Selumetinib Sulfate - Mektovi by Array Biopharma Inc, containing active ingredient Binimetinib - Viberzi by AbbVie Inc, containing active ingredient Eluxadoline - Lynparza by AstraZeneca Pharmaceuticals LP, containing active ingredient Olaparib Read More